The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 21.50
Bid: 21.00
Ask: 22.00
Change: -2.50 (-10.64%)
Spread: 1.00 (4.762%)
Open: 24.25
High: 21.00
Low: 21.00
Prev. Close: 23.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics Announces Agreement with Epic Games

25 Jul 2011 07:00

RNS Number : 9301K
Angle PLC
25 July 2011
 



For immediate release

25 July 2011

 

ANGLE plc

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES AGREEMENT WITH EPIC GAMES

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, has joined Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme.

The powerful integration of Geomerics premier cross-platform lighting solution, Enlighten, with Epic's award winning Unreal Engine 3 provides a com--pelling proposition for computer games developers. Through its membership in Epic's Unreal Engine 3 Integrated Partners Programme, Geomerics maintains code and feature parity for Enlighten in step with the engine as it evolves.

Epic's Unreal Engine 3 is designed to accelerate developers' productivity for computer and video games, mobile games and applications, training stimulations, 3D visualisations, digital films and animated televisions shows. Unreal Engine 3 is the current holder and five-time winner of Game Developer magasine's Best Engine award in the US. It is available across multiple platforms including iOS, Xbox360® and Playstation®3, PC, Mac and Android.

Geomerics' Enlighten empowers game developers by providing the ability to update all aspects of indirect lighting in real time, in game, on PC and console. Enlighten is optimised to run on Playstation®3, Xbox 360™ and PC. It is available as a stand-alone SDK, or pre-integrated into UE3.

 

Andrew Newland, Chief Executive of ANGLE commented: 

"This agreement with Epic, one of the world's leading and most successful games developers, is a great endorsement of Geomerics' cutting edge dynamic lighting technology. Association with Epic with its established customer base and trusted industry relationships can only be beneficial for Geomerics as it continues to grow its sales base."

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon, Catherine Breen

 

0207 466 5000

Scott Harris

Stephen Scott, James O'Shaughnessy, Harry Dee

 

0207 653 0030

 

 

About Epic Games

Epic Games, Inc., based in Cary, NC and established in 1991, develops cutting-edge games and cross-platform game engine technology. The company has created multiple million-selling, award-winning titles in its "Unreal" series, including "Unreal Tournament 3" for PC, PlayStation®3 and Xbox 360®. Epic's "Gears of War" franchise has sold more than 13 million copies worldwide and won more than 50 Game of the Year awards. Epic's Unreal Engine 3 is the five-time winner of and Hall of Fame inductee for Game Developer magazine's Best Engine Front Line Award. Unreal Engine 3 has also held the Develop Industry Excellence Award in its category for the past three years. Additional information about Epic can be obtained at www.epicgames.com.

 

About Geomerics

Geomerics, a 33% owned ANGLE portfolio company, is an innovation-led company developing cutting-edge graphics technology for the games industry. The company is based in Cambridge, UK, and has built a team that combines world class management and games industry experience with some of the UK's leading researchers. They are partners with many of the leading companies in the games industry and are currently working with developers around the world on AAA titles for release in 2011 and beyond.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRLLFESDVIFFIL
Date   Source Headline
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting
21st Oct 20226:15 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.